InspireMD (NYSE:NSPR) Trading Down 6.2% – Should You Sell?

Shares of InspireMD, Inc. (NYSE:NSPR) fell 6.2% during trading on Tuesday . The stock traded as low as $1.80 and last traded at $1.81. 27,137 shares were traded during trading, an increase of 2% from the average session volume of 26,712 shares. The stock had previously closed at $1.93.

InspireMD Stock Down 6.2%

The business’s 50-day simple moving average is $1.95 and its two-hundred day simple moving average is $2.25. The firm has a market cap of $76.69 million, a price-to-earnings ratio of -2.41 and a beta of 0.72.

Institutional Trading of InspireMD

Several institutional investors have recently bought and sold shares of NSPR. Huntleigh Advisors Inc. increased its position in shares of InspireMD by 5.8% in the second quarter. Huntleigh Advisors Inc. now owns 124,228 shares of the company’s stock valued at $282,000 after buying an additional 6,821 shares in the last quarter. Raymond James Financial Inc. grew its stake in InspireMD by 28.9% in the 2nd quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock valued at $101,000 after acquiring an additional 10,000 shares during the period. Citadel Advisors LLC increased its holdings in InspireMD by 45.0% in the 3rd quarter. Citadel Advisors LLC now owns 37,954 shares of the company’s stock worth $91,000 after acquiring an additional 11,778 shares in the last quarter. Rosalind Advisors Inc. raised its position in InspireMD by 0.6% during the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock worth $5,196,000 after acquiring an additional 14,109 shares during the period. Finally, Vestia Personal Wealth Advisors purchased a new position in InspireMD during the second quarter valued at $41,000. 44.78% of the stock is owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.